Infrequent diagnoses (those

with a frequency of <10 cases) were also recorded. Continuous variables were expressed as the mean and standard deviation when normally distributed, as the median and interquartile range (IQR) if distribution was skewed, and discrete variables as percentages. The Student's independent samples t-test was used to compare continuous variables and the Mann–Whitney U-test for continuous variables without a normal distribution. The association between categorical variables was evaluated using a chi-squared test (when samples were of sufficient size) or with a Fisher's exact test. Magnitude of the buy PFT�� effect was expressed as a 95% confidence interval. A p value of <0.005 was considered statistically

significant. A total of 2,993 travelers were included in the study; 11 of them were excluded because destination did not correspond with the areas included in the study. The total number of travelers analyzed was 2,982. In total, 47.8% were women; median age was 35 years (IQR 28 to 40). Median time elapsed from return to consultation was 30 days (IQR 13 to 90). Geographical areas of travel and number of travelers to each area are shown in Figure 1. The duration of travel in order of frequency was: short term in 1,594 (53.4%), long term in 710 (23.8%), and medium term in 678 (22.7%) cases. The type of travel in order of frequency was: type A in 979 (32.8%), type B in 511 (17.1%), type C in 508 (17%), and type D in 984 (33%) mTOR inhibitor cases. The age of the traveler, duration, and type of travel depending on the geographic area visited are shown in Table 1. In total, 2,062 had received a travel-related vaccine (69.1%), and the median number of vaccines received was two (IQR: 1 to

4). In order of frequency, vaccines received were: yellow fever (79.1%), typhoid fever (55.9%), tetanus–diphtheria (44%), hepatitis B (40.6%), and hepatitis A (31.8%). Complete information was available regarding malarial chemoprophylaxis in 2,568 (86.08%) cases. In total, 1,059 (35.5%) had taken malarial chemoprophylaxis, with variations according to geographical area of travel: prophylaxis was used by 54.4% of travelers to sub-Saharan Africa, 33.5% to Central Asia Southeast, 19.4% to South America, 11.5% these to the Caribbean–Central America, and 5.1% to other destinations (p < 0.05). Of these 1,059, 623 (58.8%) took chemoprophylaxis correctly. This proportion varied depending on the drug used: 57 of 71 (80.3%) taking atovaquone–proguanil did so correctly, 274 of 409 (67%) taking mefloquine, 23 of 43 (53.5%) taking doxycycline, 193 of 379 (50.9%) taking chloroquine–proguanil, and 85 of 176 (48.3%) taking chloroquine; χ2 = 43.3 (p < 0.001). More than 75% of the cases had one of the following five presenting syndromes: 1,028 (34.5%) febrile syndrome, 872 (29.